Bench to Bedside: Unlocking the promise of radioligand therapy for Australian patients
Tracks
Track 1
| Wednesday, October 30, 2024 |
| 4:05 PM - 4:50 PM |
| Plenary Room |
Overview
Sponsored by: NOVARTIS
Details
Australia is well placed to embrace and deliver on the promise of precision medicine and propel radioligand therapy from bench to bedside. There is significant opportunity for Australia to build on its global leadership in radioligand therapy research and development, by stewarding the translation of research to broad and equitable patient access while building a thriving nuclear medicine industry. To do so will require governments, industry, and academia to work collaboratively to develop a robust ecosystem that can capitalise on the health and economic potential of radioligand therapies, the next frontier in precision oncology
Speaker
Prof. Michael Hofman
Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC)
Peter MacCallum Cancer Centre
Panellist
Colleen Jen
Deputy Director - General
Queensland Health
Panellist
Ms Deanna Mill
Advisor
Evohealth
Chair
Professor Kris Thurecht
Acting Deputy Director & Group Leader, Centre for Advanced Imaging
University of Queensland
Panellist
